SOFTAD Substance Use Outcomes Following TAD

描述（由申请人提供）：药物滥用是美国青少年中的一个主要公共卫生问题，与严重的负面后果有关，包括高风险的性行为和青少年死亡的主要原因：事故、他杀和自杀。物质使用障碍（SUD）是青少年精神障碍的三种最常见的形式之一。预防这类疾病是公共卫生的优先事项。美国国家药物滥用研究所（NIDA）和国家精神健康研究所（NIMH）最近发布了RFA: DA-03-007，呼吁调查儿童精神病理学和儿童干预对随后药物滥用的影响。本项目，青少年抑郁症治疗后的物质使用结果（SOFTAD）是对完成NIMH青少年抑郁症治疗研究（TADS）的青少年的延伸随访。我们开发并正在协调TADS，这是一项12点的研究，比较认知行为疗法（CBT）、氟西汀（FLX）、CBT和FLX联合治疗在432名重度抑郁症（MDD）青少年中的急性疗效和安慰剂疗效，以及纵向疗效。TADS是第一个包括药物使用和滥用措施的青少年重度抑郁症治疗研究。我们建议加强对药物使用结果和相关家庭因素的测量，并将TADS治疗的随访期延长至5年，以解决RFA: DA-03-007中强调的关键问题。这些包括治疗重度抑郁症（和特定治疗）对随后的物质使用结果的影响，情感和物质使用领域成功结果的调节因子和中介因子的识别，以及临床样本中青少年重度抑郁症与物质使用或滥用之间的纵向关系。将每六个月跟踪和评估大约300名青少年。收集自我报告、父母报告和诊断性访谈量表。主要假设，即成功治疗重度抑郁症将减少随后的物质使用问题，以及其他问题，将使用卡方、逻辑回归和结构方程模型进行检验。SOFTAD将由杜克临床研究所（DCRI）协调，该机构与协调TADS的机构相同，从而实现了显著的效率和成本节约。

DESCRIPTION (provided by applicant): Substance abuse is a major public health problem among adolescents in the United States, associated with serious negative outcomes including high-risk sexual behavior and the leading causes of adolescent death: accidents, homicide and suicide. Substance use disorders (SUD's) are one of the three most common forms of adolescent psychiatric disturbance. Prevention of such disorders is a public health priority. The National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH) recently released RFA: DA-03-007, calling for investigations into the impact of child psychopathology and childhood interventions on subsequent drug abuse. This project, Substance use Outcomes Following Treatment for Adolescent Depression (SOFTAD) is an extended follow-up of adolescents who have completed the NIMH Treatment for Adolescents with Depression Study (TADS). We developed and are coordinating TADS, a 12-site study comparing cognitive behavior therapy (CBT), fluoxetine (FLX), combined CBT and FLX acutely to one another and to placebo, and longitudinally to one another in 432 adolescents with Major Depressive Disorder (MDD). TADS is the first adolescent MDD treatment study to include measures of substance use and abuse. We propose to enhance the measurement of substance use outcomes and related family factors and to extend the follow-up period from TADS treatment to five years in order to address critical questions emphasized in RFA: DA-03-007. These include the impact of treating MDD (and of specific treatments) on subsequent substance use outcomes, the identification of moderators and mediators of successful outcome in the affective and substance use domains, and the longitudinal relationship between adolescent MDD and substance use or abuse in a clinical sample. Approximately 300 adolescents will be followed and assessed every six months. Self-report, parent-report and diagnostic interview measures will be collected. The major hypothesis, that successful treatment of MDD will reduce subsequent substance use problems, and additional questions, will be tested using chi-square, logistic regression, and structural equation modeling. SOFTAD will be coordinated by the Duke Clinical Research Institute (DCRI), the same organization coordinating TADS, thus realizing substantial efficiencies and cost savings.